Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L9CD
|
|||
| Former ID |
DIB009167
|
|||
| Drug Name |
AZD-2115
|
|||
| Synonyms |
Dual action MABA (COPD), AstraZeneca; Dual action muscarinic acetylcholine receptor antagonist/beta 2 adrenoceptor agonist (COPD), AstraZeneca
Click to Show/Hide
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 2 | [1] | |
| Company |
AstraZeneca
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02109406) Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD. U.S. National Institutes of Health. | |||
| REF 2 | Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.